In this episode, Matt Hutzler discusses how minimizing turnaround time for ADME assays is key to managing costs.
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Hybrid Assays for Protein Bioanalysis
Assays and Why Are They Essential for Protein Bioanalysis?
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
ADME Services
Accelerating your drug discovery, preclinical and clinical programs with ADME services
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
Early Hit-to-Lead ADME Screening Bundle
Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
High Throughput ADME Screening Services
Capabilities that accelerate preclinical studies
IND-Enabling Bundle of In Vitro Assays to Assess Drug-Drug Interaction Risk
DDI Fact Sheet
In vitro ADME, LC-MS/MS bioanalysis and metabolite identification service list
Services to support your In Vitro ADME development needs
